

Quality Transformation Initiative (QTI) Memo

March 2025

The purpose of this memo aims to:

1. Provide details on the MY2024 QTI Assessment parameters by measure.
2. Share information about the expansion of the QTI CIS10 Allowance Program for the MY2024 QTI Assessment.

MY2024 QTI Assessment: Final Parameters by Measure

The following provides a detailed overview of the final parameters for QTI measures in MY2024 QTI Assessment.

- **Controlling Blood Pressure:** Controlling Blood Pressure (CBP) is included in the MY2024 HEDIS[®] for QRS¹ specifications and remains a CMS-endorsed measure. No deviations in reporting requirements.
- **Diabetes Control:** For MY2024, the Glycemic Status Assessment for Patients with Diabetes (GSD) Glycemic Status <8.0% will be used for QTI assessment. Although the QRS version of HEDIS[®] removed the <8.0% indicator, QTI reporting will follow the HEDIS[®] MY2024, Volume 2² specifications. To maintain consistency in diabetes management reporting, Covered California is requiring issuers to report the GSD <8.0% indicator via the Patient-Level Data (PLD) file.
- **Colorectal Cancer Screening[®]:** For MY2024, the assessment of colorectal cancer screening is limited to the 51-75 age band. However, issuers are required to submit data for the full 46-75 age range in the QTI PLD file. Covered California will extract the 51-75 cohort for QTI assessment. Please note that scoring assessments for QTI may differ from CMS QRS scores.

For specifications, please refer to the MY2023 HEDIS[®] specifications for QRS³ and the MY2023 HEDIS[®] QRS: Technical Update⁴. QRS issued a correction regarding the age band breakout in the technical update.

- **Childhood Immunization:** Childhood Immunization Status (Combo 10) CIS10 is included in the MY2024 HEDIS[®] for QRS¹ specifications and remains a CMS-endorsed measure. No deviations in reporting requirements.

Process for QTI PLD Submissions

Issuers must submit their **QTI PLD files by July 1, 2025**. These submissions should include patient-level data for:

- Controlling High Blood Pressure (CBP) (CBE ID #0018)
- Glycemic Status Assessment (GSD) <8.0% (CBE ID #0575)
- Colorectal Cancer Screening (COL)[®] (NQF #0034)
- Childhood Immunization Status (CIS10) (CBE ID #0038)

All other MY2024 PLD measures outlined in Article 1 must be submitted separately by **July 15, 2025**.

Submissions must follow the file naming convention:
MY2024 QTI_[Issuer Name]_[Date Submitted YYYY.MM.DD]

Files should be uploaded to the Covered California Plan Management Extranet at:
Carrier Management (Extranet) > EQT Library > Patient Level Data Files > MY_2024

Expansion of the Childhood Immunization Status Combo 10 (CIS10) Allowance Program for MY2024 QTI Assessment

Covered California is pleased to announce the expansion of the Childhood Immunization Status Combo 10 (CIS10) Allowance Program, originally introduced in 2023, to address persistent challenges in childhood immunization completion. The pilot program allowed QHP issuers to submit supplemental data for any measure denominator-eligible child who had completed the full CIS10 vaccination series but received their second influenza vaccine within 90 days after their second birthday. This program has resulted in significant benefits for participating issuers and an overall reduction in QTI payment adjustments.

Expanded Eligibility Criteria

For Measurement Year (MY) 2024, the CIS10 Allowance Program will be expanded to include **all CIS10 vaccines**, with the following updated eligibility parameters:

Extended Administration Window: Vaccinations must be administered up to 180 days after the child's second birthday to qualify for the allowance.

Rotavirus Vaccine Exception: Due to maximum age requirements, the rotavirus vaccine must still adhere to the following restrictions:

Dose 1 must be administered by 15 weeks of age

Final dose (either 2nd or 3rd) must be administered by 8 months of age

Audit Provisions: All submitted supplemental data remains subject to audit.

Applicable Dates of Service for MY2024

The extended timeframe applies to vaccinations administered between January 1, 2022, and June 30, 2025, reflecting the 180-day extension allowance.

Submission Process

The submission process for the program will remain unchanged. Interested issuers wanting to participate in the CIS10 Allowance Program are required to complete the CIS10 Allowance Program template. Completed templates must be submitted via the secure extranet portal. The deadline for these submissions is set for **July 1, 2025**. Please note that the results of the CIS10 Allowance Program are counted for **QTI assessment purposes only**.

Submissions must follow the file naming convention:

MY2024 CIS10 Allowance_[Issuer Name]_[Date Submitted YYYY.MM.DD]

Files should be uploaded to the Covered California Plan Management Extranet at:
Carrier Management (Extranet) > EQT Library > QTI Reporting > MY2024 CIS10 Allowance Program

References:

¹[MY 2024 HEDIS® for QRS](#) (2025 Quality Ratings System Measure Technical Specifications)

²HEDIS® MY 2024, Volume 2, page 162-171

³[MY 2023 HEDIS® for QRS](#) (2024 Quality Rating System Measure Technical Specifications)

⁴[Measurement Year \(MY\) 2023 HEDIS® for the Quality Rating System \(QRS\): Technical Update](#)

<https://www.ncqa.org/wp-content/uploads/QRS-HEDIS®-MY-2024-Technical-Update-Memo.pdf>

HEDIS®

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

©NCQA Copyright

- *CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.*
- *The CDC Race and Ethnicity code system was developed by the U.S. Centers for Disease Control and Prevention (CDC). NCQA's use of the code system does not imply endorsement by the CDC of NCQA, or its products or services. The code system is otherwise available on the CDC website for no charge.*

- *Certain codes are owned and copyrighted by Health Level Seven International (HL7); 2024.*
- *The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.*